OncoMatch/Clinical Trials/NCT06118710
Evaluation of the Omission of Dexamethasone in Premedication Regimens During Paclitaxel Treatment
Is NCT06118710 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Dexamethasone and H1 Antihistaminics for cancer.
Treatment: Dexamethasone · H1 Antihistaminics — This prospective multicenter randomized non-inferiority trial aims to assess whether omitting dexamethasone from the premedication regimen during paclitaxel-based chemotherapy is non-inferior to the standard of care regimen that includes dexamethasone, based on the incidence of clinically relevant hypersensitivity reactions (HSRs) of grade ≥3 as per CTCAE v5.0. With a study population of 500 adult patients with solid tumors, the trial will also investigate secondary endpoints including the severity and incidence of HSRs of any grade, the number of paclitaxel administrations until the first HSR, the impact on patients' quality of life, adverse events related to dexamethasone, and the cost-effectiveness of the two premedication regimens from healthcare and societal perspectives.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: paclitaxel-based regimen (paclitaxel)
Prior treatment with a paclitaxel-based regimen
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify